892113-81-4

Basic information

• Product Name: (3R)-4-[(3R)-3-(tert-butyloxycarbonylamino)-4-(2,4,5-trifluorophenyl) butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepin-2-one
• Synonyms: (3R)-4-[(3R)-3-(tert-butyloxycarbonylamino)-4-(2,4,5-trifluorophenyl) butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepin-2-one
• CAS NO: 892113-81-4
• Molecular Weight: 511.464
• Mol File: 892113-81-4.mol

Chemical Properties

• CAS DataBase Reference: (3R)-4-[(3R)-3-(tert-butyloxycarbonylamino)-4-(2,4,5-trifluorophenyl) butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3R)-4-[(3R)-3-(tert-butyloxycarbonylamino)-4-(2,4,5-trifluorophenyl) butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepin-2-one(892113-81-4)
• EPA Substance Registry System: (3R)-4-[(3R)-3-(tert-butyloxycarbonylamino)-4-(2,4,5-trifluorophenyl) butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepin-2-one(892113-81-4)

Safety Data

• Hazardous Substances Data: 892113-81-4(Hazardous Substances Data)

Upstream product

• 209995-38-0 (2,4,5-trifluorophenyl)acetic acid 
• 1152439-73-0 2,2-dimethyl-5-[2-(2,4,5-trifluorophenyl)acetyl]-[1,3]dioxane-4,6-dione 
• 892113-72-3 4-[(2Z)-3-amino-4-(2,4,5-trifluorophenyl)but-2-enoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one 
• 892113-66-5 4-[3-oxo-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one 
• 892113-47-2 2-[(3-aminopropyl)amino]-4,4,4-trifluorobutanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 486460-00-8 (3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoic acid 
• 892113-88-1 4-[(3R)-3-(tert-butyloxycarbonylamino)-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepin-2-one 

Downstream Products

• 892114-11-3 (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepin-2-one hydrochloride salt 

Relevant articles and documents

(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

Replacement of the triazolopiperazine ring of sitagliptin (DPP-4 IC50 = 18 nM) with 3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one gave dipeptidyl peptidase IV (DPP-4) inhibitor 1 which is potent (DPP-4 IC50 = 2.6 nM), selective, and ef

TARTARIC ACID SALTS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

Tartaric acid salts of (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl) butanoyl]hexahydro-3-(2,2,2-trifluoroethyl)-2H-1,4-diazepin-2-one are potent inhibitors of dipeptidyl peptidase-IV and are useful for the prevention and/or treatment of non-insulin depe

PROCESS TO CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION

The present invention relates to a process for the efficient preparation of enantiomerically enriched beta amino acid derivatives which are useful in the asymmetric synthesis of biologically active molecules. The process comprises an enantioselective hydrogenation of a prochiral beta amino acrylic acid derivative substrate in the presence of a transition metal precursor complexed with a chiral ferrocenyl diphosphine ligand with in situ protection of the primary amine product. The invention also relates to a novel process for the preparation of chiral beta-amino acid amides as inhibitors of the dipeptidyl peptidase-IV of structural formula III and the useful intermediates obtained therein. The products resulting from the instant process are inhibitors of dipeptidyl peptidase-IV and thereby useful for the treatment of Type 2 diabetes.